Jim Cramer - Mad MoneyInsmed INSMWATCHJan 05, 2026
Up 152% last year. They got FDA approval for one of their top drugs last year to treat a lung condition. It pulled back 18% last month due to a disappointing trial result in a drug. Worth watching this.
Up 152% last year. They got FDA approval for one of their top drugs last year to treat a lung condition. It pulled back 18% last month due to a disappointing trial result in a drug. Worth watching this.